. Author manuscript; available in PMC: 2013 Oct 1.

Published in final edited form as: Complement Ther Med. 2012 Apr 27;20(5):283–290. doi: 10.1016/j.ctim.2012.04.002

Table 1.

Adjusted ^aHazard Ratios (HR) of time to additional breast cancer events and all-cause mortality in relation to systemic (chemotherapy/anti-estrogen) treatment use in a cohort of breast cancer survivors enrolled in the WHEL Study.

		Additional Breast Cancer Events		All-cause Mortality

	Sample size (n)	event	HR (95% CI)	event	HR (95% CI)
Any systemic treatment	2909	484	reference	295	reference
No systemic treatment	177	34	1.9 (1.32, 2.73)	20	1.7 (1.06, 2.73)

Cox regression models were adjusted for age at randomization, tumor stage, and time since diagnosis.